Tissue inhibitor of metalloproteinase (TIMP)-1 predicts failure of recovery of ejection fraction in acute heart failure with reduced ejection fraction

• Published in: Open heart Vol. 11; no. 2; p. e002770
• Main Authors: Tseng, Chih-Hsueh, Huang, Wei-Ming, Chang, Hao-Chih, Yu, Wen-Chung, Cheng, Hao-Min, Chiang, Chern-En, Chen, Chen-Huan, Sung, Shih-Hsien
• Format: Journal Article
• Language: English
• Published: England British Cardiovascular Society 25.09.2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Acute coronary syndromes; Acute Disease; Aged; Aged, 80 and over; Biomarkers; Biomarkers - blood; Cardiomyopathy, Dilated; Cardiovascular disease; Chronic obstructive pulmonary disease; Echocardiography; Ejection fraction; Female; Flow velocity; Follow-Up Studies; Gender; Heart attacks; Heart failure; Heart Failure - blood; Heart Failure - diagnosis; Heart Failure - physiopathology; Heart Failure and Cardiomyopathies; Heart Failure, Systolic; Hospitalization; Humans; Male; Matrix Metalloproteinase 9 - blood; Medical prognosis; Middle Aged; Mortality; Natriuretic Peptide, Brain - blood; Original Research; Peptide Fragments - blood; Peptides; Predictive Value of Tests; Prognosis; Prospective Studies; Pulmonary arteries; R&D; Recovery of Function; Research & development; Stroke Volume - physiology; Time Factors; Tissue Inhibitor of Metalloproteinase-1 - blood; Ventricular Function, Left - physiology; United Kingdom > UK; Biomarkers; Echocardiography; Heart Failure, Systolic; Cardiomyopathy, Dilated

BackgroundHeart failure (HF) with improved ejection fraction (HFimpEF) is a recently identified phenotype of HF, which had better cardiovascular outcomes compared with persistent HF with reduced ejection fraction (HFrEF). The present study aimed to investigate the predictive value of tissue inhibito...